September 18, 2023
Published by Melanie Hurley Iveagh at September 18, 2023
Categories

Afimmune’s Epeleuton is granted both FDA Rare Pediatric Disease and Fast Track Designations for the treatment of Sickle Cell Disease

Dublin, Ireland, 18 September 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted […]
Do you like it?0
Read more
June 19, 2023
Published by Melanie Hurley Iveagh at June 19, 2023
Categories

Afimmune joins the Sickle Cell Disease Association of America’s Collaboration of Advocates for Research, Education and Science (C.A.R.E.S.) Consortium

Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease […]
Do you like it?0
Read more
June 5, 2023
Published by Melanie Hurley Iveagh at June 5, 2023
Categories

Data Showing Epeleuton Reduces Endothelial Adhesion Of Red Blood Cells From Sickle Cell Disease Patients Will Be Presented At The EHA 2023 Congress

Dublin, Ireland, 5 June 2023: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology […]
Do you like it?0
Read more
March 29, 2023
Published by Melanie Hurley Iveagh at March 29, 2023
Categories

Afimmune to Host KOL Webinar on Sickle Cell Disease: The Changing Landscape and Need for New Treatments

Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a […]
Do you like it?0
Read more
January 4, 2023
Published by Melanie Hurley Iveagh at January 4, 2023
Categories

Afimmune Confirm Alignment with FDA on Planned Pivotal Trial of Epeleuton in Sickle Cell Disease Patients

Afimmune looking to initiate Pivotal study in 2023 Dublin, Ireland, 4 January 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the […]
Do you like it?0
Read more
September 19, 2022
Published by Melanie Hurley Iveagh at September 19, 2022
Categories

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the EMA

Dublin, Ireland, 19 September 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation […]
Do you like it?0
Read more
July 19, 2022
Published by Melanie Hurley Iveagh at July 19, 2022
Categories

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the FDA

Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
Do you like it?0
Read more
June 10, 2022
Published by Melanie Hurley Iveagh at June 10, 2022
Categories

Data Showing Epeleuton As A Potential Treatment For Sickle Cell Disease Will Be Presented At The EHA 2022 Congress

Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
Do you like it?0
Read more
August 26, 2021
Published by Melanie Hurley Iveagh at August 26, 2021
Categories

Afimmune’s Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study

Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]
Do you like it?0
Read more